Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )

NCT07720921 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma of the Renal Pelvis and Ureter
Neoadjuvant Therapy

Interventions

RADIATION: Neoadjuvant radiotherapy
DRUG: ADC + PD1 monoclonal antibody

Sponsor

Peking University First Hospital